Co-Authors
This is a "connection" page, showing publications co-authored by MARIA A RODRIGUEZ and BARRY I SAMUELS.
Connection Strength
0.218
-
Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2005 Feb 01; 23(4):667-75.
Score: 0.063
-
Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytes. Oncol Rep. 2003 Sep-Oct; 10(5):1513-8.
Score: 0.057
-
Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2009 Nov 01; 27(31):5213-8.
Score: 0.022
-
Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma. Br J Haematol. 2007 Feb; 136(3):439-47.
Score: 0.018
-
High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol. 2005 Oct 01; 23(28):7013-23.
Score: 0.017
-
Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma. J Clin Oncol. 2004 Oct 15; 22(20):4095-102.
Score: 0.015
-
Irinotecan in relapsed or refractory non-Hodgkin's lymphomas. Indications of activity in a phase II trial. Oncology (Williston Park). 2002 Aug; 16(8 Suppl 7):27-31.
Score: 0.013
-
Paclitaxel plus topotecan treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma. Ann Oncol. 2001 Jul; 12(7):923-7.
Score: 0.012